Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis

International Journal of Oncology

Volumn 52, Issue 3, 2018, Pages 1011-1022

  Yamaguchi, Yuki ^a,b   Kasukabe, Takashi ^a   Kumakura, Shunichi ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b Masuda Red Cross Hospital   (Japan)

Author keywords

Cotylenin A; Ferroptosis; Pancreatic cancer cells; Piperlongumine; Sulfasalazine

Indexed keywords

ACETYLCYSTEINE; APOPTOSIS INHIBITOR; AURANOFIN; CHONDROITIN SULFATE IRON; DEFEROXAMINE; DNA; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUTATHIONE; IRINOTECAN; IRON CHELATING AGENT; OXALIPLATIN; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; SORAFENIB; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; COTYLENIN A; CYCLOHEXYLAMINE DERIVATIVE; DITERPENE; FERROSTATIN-1; IRON; LIPROXSTATIN-1; PEPTIDE CHLOROMETHYL KETONE; PHENYLENEDIAMINE DERIVATIVE; PIPERLONGUMININE; QUINOXALINE DERIVATIVE; SPIRO COMPOUND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA SYNTHESIS; FERROPTOSIS; HUMAN; HUMAN CELL; MIA PACA-2 CELL LINE; MORTALITY RATE; PANC-1 CELL LINE; PANCREAS CANCER; PLANT GROWTH; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; FIBROBLAST; METABOLISM; MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL LINE, TUMOR; CYCLOHEXYLAMINES; DEFEROXAMINE; DIOXOLANES; DITERPENES; DRUG SYNERGISM; FIBROBLASTS; HUMANS; IRON; MICE; PANCREATIC NEOPLASMS; PHENYLENEDIAMINES; QUINOXALINES; REACTIVE OXYGEN SPECIES; SPIRO COMPOUNDS; SULFASALAZINE;

EID: 85041598801     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2018.4259     Document Type: Article

References (42)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Han X, Saiyin H, Zhao J, Fang Y, Rong Y, Shi C, Lou W and Kuang T: Overexpression of MIR-135b-5p promotes unfavorable clinical characteristics and poor prognosis via the repression of SFRP4 in pancreatic cancer. Oncotarget 8: 62195-62207, 2017.
3. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
4. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
5. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
6. Kroep JR, Pinedo HM, van Groeningen CJ and Peters GJ: Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 10 (Suppl 4): 234-238, 1999.
7. Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A and Dambrauskas Z: HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol 21: 13004-13019, 2015.
8. Zhong S, Qie S, Yang L, Yan Q, Ge L and Wang Z: S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer. A meta-analysis (PRISMA) of randomized control trial. Medicine (Baltimore) 96: e7611, 2017.
9. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N and Jacks T: Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 108: 8773-8778, 2011.
10. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249, 2006.
11. Honma Y, Ishii Y, Yamamoto-Yamaguchi Y, Sassa T and Asahi K: Cotylenin A, a differentiation-inducing agent, and IFN-alpha cooperatively induce apoptosis and have an antitumor effect on human non-small cell lung carcinoma cells in nude mice. Cancer Res 63: 3659-3666, 2003.
12. Kasukabe T, Okabe-Kado J, Kato N, Sassa T and Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7: R1097-R1110, 2005.
13. Kasukabe T, Okabe-Kado J, Kato N, Honma Y and Kumakura S: Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells. Int J Oncol 46: 841-848, 2015.
14. Yang WS and Stockwell BR: Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 15: 234-245, 2008.
15. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149: 1060-1072, 2012.
16. Yang WS and Stockwell BR: Ferroptosis: Death by lipid peroxidation. Trends Cell Biol 26: 165-176, 2016.
17. Latunde-Dada GO: Ferroptosis: Role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta 1861: 1893-1900, 2017.
18. Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B and Singh SV: Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 285: 26558-26569, 2010.
19. Hong Y-H, Uddin MH, Jo U, Kim B, Song J, Suh DH, Kim HS and Song YS: ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis. Front Oncol 5: 167, 2015.
20. Kasukabe T, Honma Y, Okabe-Kado J, Higuchi Y, Kato N and Kumakura S: Combined treatment with cotylenin A and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells. Oncol Rep 36: 968-976, 2016.
21. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-234, 2011.
22. Dhillon H, Mamidi S, McClean P and Reindl KM: Transcriptome analysis of piperlongumine-treated human pancreatic cancer cells reveals involvement of oxidative stress and endoplasmic reticulum stress pathways. J Med Food 19: 578-585, 2016.
23. Jin HO, Park JA, Kim HA, Chang YH, Hong YJ, Park IC and Lee JK: Piperlongumine downregulates the expression of HER family in breast cancer cells. Biochem Biophys Res Commun 486: 1083-1089, 2017.
24. Alpay M, Yurdakok-Dikmen B, Kismali G and Sel T: Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro. J Cancer Res Ther 12: 556-560, 2016.
25. Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, et al: Structural and biochemical analyses reveal the mechanism of glutathione S-transferase pi 1 inhibition by the anti-cancer compound piperlongumine. J Biol Chem 292: 112-120, 2017.
26. Chen SY, Liu GH, Chao WY, Shi CS, Lin CY, Lim YP, Lu CH, Lai PY, Chen HR and Lee YR: Piperlongumine suppresses proliferation of human oral squamous cell carcinoma through cell cycle arrest, apoptosis and senescence. Int J Mol Sci 17: 616, 2016.
27. Wang Y, Wang JW, Xiao X, Shan Y, Xue B, Jiang G, He Q, Chen J, Xu HG, Zhao RX, et al: Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis 4: e824, 2013.
28. Liu QR, Liu JM, Chen Y, Xie XQ, Xiong XX, Qiu XY, Pan F, Liu D, Yu SB and Chen XQ: Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways. Oxid Med Cell Longev 2014: 653732, 2014.
29. Chen Y, Liu JM, Xiong XX, Qiu XY, Pan F, Liu D, Lan SJ, Jin S, Yu SB and Chen XQ: Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP. Oncotarget 6: 6406-6421, 2015.
30. Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R and Tang D: Ferroptosis: Process and function. Cell Death Differ 23: 369-379, 2016.
31. Sassa T, Tojyo T and Munakata K: Isolation of a new plant growth substance with cytokinin-like activity. Nature 227: 379, 1970.
32. Jiang L, Kon N, Li T, Wang S-J, Su T, Hibshoosh H, Baer R and Gu W: Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520: 57-62, 2015.
33. Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, et al: Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551: 247-250, 2017.
34. Ma S, Henson ES, Chen Y and Gibson SB: Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis 7: e2307, 2016.
35. Zou P, Xia Y, Ji J, Chen W, Zhang J, Chen X, Rajamanickam V, Chen G, Wang Z, Chen L, et al: Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer. Cancer Lett 375: 114-126, 2016.
36. Wang Y, Wu X, Zhou Y, Jiang H, Pan S and Sun B: Piperlongumine suppresses growth and sensitizes pancreatic tumors to gemcitabine in a xenograft mouse model by modulating the NF-kappa B pathway. Cancer Prev Res (Phila) 9: 234-244, 2016.
37. Kwon MY, Park E, Lee SJ and Chung SW: Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6: 24393-24403, 2015.
38. Lee HN, Jin HO, Park JA, Kim JH, Kim JY, Kim B, Kim W, Hong SE, Lee YH, Chang YH, et al: Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine. Mol Cells 38: 327-335, 2015.
39. Kawakami K, Hattori M, Inoue T, Maruyama Y, Ohkanda J, Kato N, Tongu M, Yamada T, Akimoto M, Takenaga K, et al: A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts. Anticancer Agents Med Chem 12: 791-800, 2012.
40. Kasukabe T, Okabe-Kado J, Haranosono Y, Kato N and Honma Y: Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells. Int J Oncol 42: 767-775, 2013.
41. Miyake T, Honma Y, Urano T, Kato N and Suzumiya J: Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells. Int J Oncol 47: 315-324, 2015.
42. Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, et al: Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547: 453-457, 2017.